United Therapeutics has achieved a clinically meaningful milestone: two Phase 3 trials of nebulized Tyvaso in IPF have both met primary endpoints, with TETON-1 reportedly exceeding the effect size of TETON-2. This is a substantive positive development that justifies analyst price target increases and the market's single-day re-rating. The planned sNDA submission by summer 2026 sets a concrete near-term regulatory catalyst. However, approval remains uncertain, the full data set has not yet been disclosed, and the commercial opportunity is subject to competitive, reimbursement, and execution risks that analyst estimates do not fully reflect. The CEO and director's same-day option sales under pre-arranged plans, while routine, should not be conflated with bullish insider buying. The stock's current trading level near analyst consensus targets suggests limited near-term upside without additional catalysts, with medium-term value dependent on regulatory progress and eventual commercial execution.